How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

Draft guidance consultation

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

2 Information about inhaled treprostinil

Anticipated marketing authorisation indication

2.1

Inhaled treprostinil (confidential brand name, Ferrer) does not have a marketing authorisation in the UK yet. The anticipated marketing authorisation for inhaled treprostinil is for 'the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability'.

Dosage in the marketing authorisation

2.2

The dosage schedule will be available in the summary of product characteristics for inhaled treprostinil.

Price

2.3

The list price of inhaled treprostinil is confidential.

2.4

The company has a commercial arrangement, which would have applied if inhaled treprostinil had been recommended.

Sustainability

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Ferrer will be included here when guidance is published.